We lead Innovation

GENOME INSIGHT collaborates with major hospitals and leading pharmaceutical companies in Korea and around the world.
We are building the foundation for precision medicine with our experience, technical expertise, and infrastructure.

Provided below are brief introductions to our ongoing projects.
We are opened to new partners, collaborators, and funding bodies wishing to shape a changing world with GENOME INSIGHT.
We also look forward to working with companies wishing to benefit from our growing database.

  • 1K Liver Cancer Project

    We are exploring 1,000 Korean hepatocellular carcinoma cases. Due to high HBV and HCV infection rates, liver cancer is among the most prevalent cancer type in Korea and in Asian countries. GENOME INSIGHT is producing and analyzing whole-genome sequences of cancers and their counterpart normal samples. Collaborating with Seoul National University Hospital, patient medical history including prognosis and responses to therapeutics are simultaneously collected to the database.

  • 1K Lung Adenocarcinoma Project

    We are exploring 1,000 Korean lung cancer cases. We target 500 early stage lung adenocarcinomas (surgical specimens) as well as 500 advanced late-stage tumors collected from metastatic/relapsed tissues. Unlike the Western population, lung adenocarcinomas in Koreans (and Asians) are more frequently developed in non-smokers (30-40%), and more than 50% of the tumors harbor EGFR gain-of-function mutation. GENOME INSIGHT is producing and analyzing whole-genome sequences of cancers and their counterpart normal samples. Collaborating with Seoul National University Hospital, patient medical history including prognosis and responses to therapeutics (including 3rd generation EGFR inhibitors) are simultaneously collected to the database.

  • 500 Breast Cancer Project

    We are exploring 500 Korean breast cancer cases. We correlate whole-genome landscape of breast cancers with their therapeutic responses including neoadjuvant therapy (surgical specimens). Compared to the Western society breast cancer develops more frequently in the younger population in Korea (~50 yrs age, ~1-2 decades earlier), but its underlying stimulator is currently unknown. GENOME INSIGHT is producing and analyzing whole-genome sequences of cancers and their counterpart normal samples. Collaborating with Seoul St. Mary’s Hospital and Samsung Medical Center, patient medical history including prognosis and responses to therapeutics are simultaneously collected to the database.

  • 300 Gastro-Intestinal Stromal Tumors (GIST)

    We are exploring 300 GIST genomes. GISTs are soft tissue sarcomas that develop in the digestive tract, such as the stomach. A substantial fraction of GIST shows good response to targeted therapy, such as Imatinib. We are investigating the whole-genome landscape to predict the drug response and understand the clonal evolution of GIST tumors under selective pressure of tyrosine kinase inhibitors. GENOME INSIGHT is producing and analyzing whole-genome sequences of cancers and their counterpart normal samples. Collaborating with Asan Medical Center, patient medical history including prognosis and responses to therapeutics are simultaneously collected to the database.

  • Whole-genomes for orphan diseases

    Whole-genome sequencing enables comprehensive detection of disease-causing mutations. In particular, WGS can detect intergenic/intronic mutations, copy number changes, genomic rearrangements, and mobilization of retrotransposons (e.g. LINE-1), which are not feasibly detected with other modalities. We are collaborating with hospitals and clinicians to help patients with rare diseases, often left undiagnosed in clinical settings. We believe our service can shed light to the unknown diseases by providing guidance for accurate diagnosis and smart therapeutic strategies.

    This project is opened for all patients and clinicians seeking for solution. Please contact us if you wish to participate!

    project@genomeinsight.com

Partners